MoneyThe story, in brief
Alphabet’s Isomorphic Labs reportedly raising $2B+ for its medical research AI
$2B+. That's what Alphabet's Isomorphic Labs is raising to weaponize AI for drug discovery—and it signals where the real money is moving in biotech.
The KeyNews take
Why it matters
Alphabet is doubling down on AI-driven drug discovery with a massive funding round, signaling institutional confidence in AI's ability to compress development timelines and reduce R&D costs in pharma—a sector where AI adoption has been slower than software.
The key facts
4 to knowIsomorphic Labs raising $2B+ in new funding round
Thrive Capital (OpenAI backer) leading the round as existing investor
Alphabet subsidiary focused on accelerating drug development via AI
Signals major capital flowing into AI-for-biotech vertical
Go to the source
SiliconAnglesiliconangle.com
Publisher excerpt: Isomorphic Labs Inc., an Alphabet Inc. unit using artificial intelligence to speed up drug development, is reportedly in talks to raise a new funding round. Sources told Bloomberg today that the investment could be worth more than $2 billion. OpenAI Group PBC backer Thrive Capital, an existing…